In Hospital Course of Acute Coronary Artery Syndromes
HACSA
Evaluation of in- Hospital Course of Acute Coronary Syndromes in the Contempory Area
1 other identifier
observational
269
1 country
1
Brief Summary
While international guidelines have indicated that use of a routine invasive strategy was favored for high-risk patients with NSTE-ACS and for all STE- ACS, the lower risk patients successfully reperfused and carrefully selected may perhaps not benefit of this systematic strategy. Evaluation of complications occurring in a contemporary population of ACS may help to evaluate the need of ICU strategy. Coupled with favorable outcomes in many patients, these data may be an opportunity for testing of strategies to refine triage to less costly hospital care units. The investigators thus want to compare, through an observational and prospective study, the event rate of two groups of patients with ACS admitted to ICU . Patients are classified as "high risk" and "low risk" according to specific medical criteria validated in the literature. The study will include all consecutive patients admitted for NSTACS and STACS admitted to the intensive care department of the Montpellier university hospital with the diagnosis of ACS confirmed by coronary angiography. Our primary goal is to compare the percentage of patients with at least one serious clinical event between the high and low risk groups. A serious event is defined by the occurrence within 7+/-5 days of one of the following criteria: death all causes, serious neurological or hemorrhagic complications, hemodynamic instability and severe heart failure, rhythm or sustained or poorly tolerated conduction disorders requiring therapeutic intervention, painful recurrence requiring new coronary angiography, secondary transfer to intensive care for any reason. Our hypothesis is that low-risk patients will have very few events and no fatal events and that they could not require intensive care unit admission .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2019
CompletedFirst Submitted
Initial submission to the registry
May 4, 2020
CompletedFirst Posted
Study publicly available on registry
May 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2020
CompletedJuly 29, 2020
July 1, 2020
1.1 years
May 4, 2020
July 28, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
clinical evaluation during hospitalization
all causes of death, serious neurological or hemorrhagic complications, hemodynamic instability and severe heart failure, rhythm or sustained or poorly tolerated conduction disorders requiring therapeutic intervention, chest pain recurrence requiring new coronary angiography, secondary transfer to intensive care for any reason
1 day
Secondary Outcomes (1)
all-cause and cardiovascular mortality
1 month
Study Arms (1)
ACS
All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
Eligibility Criteria
All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
You may qualify if:
- Patients all admitted in ICU after coronary angiography and angioplasty if required
You may not qualify if:
- Patients not admitted in ICU
- Patients without coronary angiography evaluation
- lack of patient consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Uhmontpellier
Montpellier, 34295, France
Related Publications (1)
Akodad M, Meunier PA, Padovani C, Cayla G, Zitouni W, Macia JC, Robert P, Steinecker M, Roubille F, Leclercq F. Identification of Low- versus High-Risk Acute Coronary Syndrome for a Selective ECG Monitoring Strategy. J Clin Med. 2023 Jul 11;12(14):4604. doi: 10.3390/jcm12144604.
PMID: 37510718DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Florence Leclercq, MD, PhD
University Hospital, Montpellier
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 4, 2020
First Posted
May 7, 2020
Study Start
May 1, 2019
Primary Completion
May 31, 2020
Study Completion
July 1, 2020
Last Updated
July 29, 2020
Record last verified: 2020-07